Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Its symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck, and behind the ears.
The Rubella pipeline drugs market research report provides comprehensive information on the therapeutics under development for Rubella, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella and features dormant and discontinued projects.
Rubella Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Rubella pipeline products market are subcutaneous and intradermal.
Rubella Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Rubella pipeline products market, download a free report sample
Rubella Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Rubella pipeline products market are vaccine, live attenuated vaccine, and subunit vaccine.
Rubella Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Rubella pipeline products market, download a free report sample
Rubella Pipeline Products Market – Competitive Landscape
The leading companies in the Rubella pipeline products market are Beijing Minhai Biotechnology Co Ltd, Amogen Pharma Pvt Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Vaxxas Inc, Zhongyianke Biotech Co Ltd, and Zydus Lifesciences Ltd.
Rubella Pipeline Products Market Analysis by Companies
To know more about the leading players in the Rubella pipeline products market, download a free report sample
Rubella Pipeline Products Market Report Overview
Key Routes of Administration | Subcutaneous and Intradermal |
Key Molecule Type | Vaccine, Live Attenuated Vaccine, and Subunit Vaccine |
Leading Companies | Beijing Minhai Biotechnology Co Ltd, Amogen Pharma Pvt Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Vaxxas Inc, Zhongyianke Biotech Co Ltd, and Zydus Lifesciences Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Beijing Minhai Biotechnology Co Ltd
Daiichi Sankyo Co Ltd
Enesi Pharma Ltd
Indian Immunologicals Ltd
Micron Biomedical Inc
Sinovac Biotech Ltd
Vaxxas Inc
Zhongyianke Biotech Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key routes of administration in the Rubella pipeline products market?
The key routes of administration in the Rubella pipeline products market are subcutaneous and intradermal.
-
What are the key molecule types in the Rubella pipeline products market?
The key molecule types in the Rubella pipeline products market are vaccine, live attenuated vaccine, and subunit vaccine.
-
Which are the leading companies in the Rubella pipeline products market?
The leading companies in the Rubella pipeline products market are Beijing Minhai Biotechnology Co Ltd, Amogen Pharma Pvt Ltd, Daiichi Sankyo Co Ltd, Enesi Pharma Ltd, Indian Immunologicals Ltd, Micron Biomedical Inc, Sinovac Biotech Ltd, Vaxxas Inc, Zhongyianke Biotech Co Ltd, and Zydus Lifesciences Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.